PETALING JAYA: Pharmaniaga Bhd
is poised for continued improvement as it rides on vaccine sales in the near term while leveraging a potential renewal of its concession agreement for longer-term growth.
Analysts remained upbeat on the group’s prospects, following its fourth-quarter (Q4) results briefing on Monday.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
